Thymosin Beta-4, TB-500, and Follicle Stem Cells: An Animal-Data Review

TB-500 has a hair reputation that belongs to a different molecule. Almost everything written about the peptide and hair cites research on thymosin beta-4, a protein of 43 residues that is abundant in most mammalian cells, and TB-500 is a seven-residue fragment of it, sequence LKKTETQ, that corresponds to a short stretch of the parent protein. The FDA placed the fragment by name in category 2 of its 503A bulk substances policy and the nomination was withdrawn in April 2026, no thymosin beta-4 or TB-500 product is FDA-approved for any hair indication, and the hair literature, which is real and interesting, is animal literature on the parent protein. A practice that encounters TB-500 in a formulary is well served by knowing which molecule the evidence describes.

This article sets out the two molecules, what the rodent and goat studies of thymosin beta-4 report, what the follicle-cell and transcriptomic work adds, why none of it transfers to the fragment without evidence, and the regulatory position. It attributes every finding to the study that reported it, makes no claim about what either molecule does to human hair, and leaves the prescribing decision with the prescriber. The peptide evidence page on TB-500 under the Science section of this site draws the same distinction for the peptide in general.

A sentence and a word from it: what the two molecules are

Thymosin beta-4 is a 43-residue protein whose principal established job is binding monomeric actin, holding a pool of unpolymerised actin available for the cytoskeleton, which makes it a housekeeping protein of cell structure and motility rather than a signalling hormone. Ying and colleagues reviewed its actin-binding modes and biological functions in Current Protein and Peptide Science in 2023, and that review is the place to start for the parent protein.

TB-500 is a seven-residue fragment, LKKTETQ, corresponding to part of the protein’s actin-binding region. An analogy that holds for the size of the difference and not for any biology is a sentence and one word lifted from it: the word is genuinely part of the sentence, and it does not carry the sentence’s meaning on its own. The FDA’s own listing preserves the distinction, naming the substance as thymosin beta-4 fragment LKKTETQ, also known as TB-500, and a formulary entry that cites thymosin beta-4 research for a TB-500 vial is citing the sentence for the word.

The hair literature is rodent and goat literature on the parent protein

Philp and colleagues reported in the FASEB Journal in 2004 that thymosin beta-4 increased hair growth in rats and mice, that a subset of follicular keratinocytes expressed the protein in a coordinated way across the hair cycle, and that clonogenic keratinocytes related to bulge stem cells showed increased migration and differentiation in its presence at nanomolar concentrations. The same group reported in the Annals of the New York Academy of Sciences in 2007 that the protein induced hair growth through stem cell migration and differentiation. Those two papers are the origin of every hair claim made for the peptide market, and both studied the 43-residue protein in rodents.

The literature since 2011 has stayed in animals and cells. Gao and colleagues reported in PLoS One in 2015 that thymosin beta-4 induced mouse hair growth. A group working on cashmere goats reported in 2019 that a CRISPR knock-in of the gene was generated and that overexpression in follicle tissue increased cashmere yield, and reported in the International Journal of Molecular Sciences in 2020 that the protein, identified by transcriptomic analysis across the anagen to telogen transition, promoted proliferation of secondary follicle dermal papilla cells. Dai and colleagues reviewed the protein’s potential roles in follicle growth and development in the Journal of Cellular and Molecular Medicine in 2021. It is a coherent body of work, it concerns the parent protein, and no part of it is a human study.

• 2004 and 2007: thymosin beta-4 in rats and mice, follicle stem cell activation and migration.
• 2015: thymosin beta-4 induced mouse hair growth.
• 2019 and 2020: gene knock-in and overexpression in cashmere goats; dermal papilla cell proliferation.
• 2021 and 2023: reviews of the protein’s follicle roles and its actin biology.
• Human hair trials of thymosin beta-4 or of TB-500: none published.

Why the goat and mouse data do not transfer to a seven-residue vial

Three transfers would have to hold for the animal literature to describe a TB-500 preparation, and none has been shown. The finding would have to transfer from the protein to the fragment, which is a chemistry question the fragment’s much smaller literature has not answered; from rodents and goats to humans, which is the ordinary preclinical gap; and from the concentrations and routes the studies used to whatever a compounded preparation delivers. The dermal papilla biology that the thymosin beta-4 work touches, including the Wnt signalling that Lim and Nusse review, is real, and it is the same biology every signalling molecule in this series is studied against; the question is which molecule was in the experiment.

The specialty reviews published in 2026 read the fragment that way. Mendias and Awan in Sports Medicine and Tewari and colleagues in the American Journal of Sports Medicine group TB-500 with other unapproved peptides and describe the human evidence as insufficient to support use, in the musculoskeletal context where most of its market lives. Hair is not a context either review addresses, because there is no human hair data to address.

Where the fragment sits in a formulary, and beside what

Compounded formularies list TB-500 on its own and in blends with BPC-157, KPV and GHK-Cu, and it is the blend with GHK-Cu that brings the fragment into a hair conversation, because GHK-Cu has its own follicle literature, discussed in the copper peptide article of this series and in the 2018 review by Pickart and Margolina. A blend does not inherit the evidence of its parts, and the GHK-Cu evidence is itself organ culture with a related peptide, so a four-peptide vial arrives with four separate rationales of very different strength and no study of the vial.

Every such preparation is prepared under section 503A to an individual prescription and has not been evaluated by the FDA for safety, effectiveness or quality, as the FDA’s questions and answers on compounding state. The FDA placed the TB-500 fragment in category 2 of its 503A bulk substances policy and the nomination was withdrawn in April 2026, with a rationale that concerns immunogenicity risk from aggregation and peptide-related impurities, and the TB-500 evidence page on this site reproduces that rationale verbatim. ExaVeyra does not offer TB-500 for sale; the fragment is discussed here because it appears in the formulary landscape a hair practice reads, and the distinction between it and the protein is most of what a reader needs.

Closing Observation

The thymosin beta-4 hair literature is a genuine animal literature: two decades of rodent, goat and follicle-cell work reporting stem cell activation, dermal papilla proliferation and hair growth in models. TB-500 is a seven-residue fragment of the protein those studies used, its own literature is small and does not include hair, and the FDA placed it by name in category 2 of its bulk substances policy before the nomination was withdrawn. The distance between the two molecules is the whole story, and once seen it is difficult to unsee.

What the literature does not support is the substitution the market performs, in which the protein’s research is placed beside the fragment’s vial as though they were one. A practice that holds the two apart will read a formulary entry for what it is, will approach a four-peptide blend as four separate questions, and will be considerably harder to sell a fragment to on the strength of a protein’s results in a goat.